For companies with multiple common share classes, market capitalization includes both classes. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. Market Capitalization Reflects the total market value of a company. Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Both assets are invaluable to Lumen’s mission to make antibody drugs available to mass-market applications for the first time.P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. He has played important roles at various startups, including Sapphire Energy (as head of R&D) and Syrrx (acquired by Takeda Pharmaceuticals), reflecting not only the scientific firepower he brings to the table but also his management expertise. He began his career in protein engineering and X-ray crystallography-both critical tools for the development of antibodies-before transitioning to the development of small-molecule drug discovery, and then finally to finding industrial applications for photosynthetic microbes. Of special significance to Lumen, Jim’s front-row seat on the development of the field provides a kind of institutional memory that dates back long before the company’s actual founding.Ĭolumbia University Vagelos College of Physicians and Surgeons, MD, PhD, Medicine/BiochemistryĬraig’s unusual intersection of expertise in drug development and microbiology is a precise match for Lumen’s core science and its ability to deliver novel biologic drugs to patients at unprecedented scale. Ten years as an Investigator at the prestigious Howard Hughes Medical Institute in the 1990s and early 2000s, followed by six years as Director of Basic Sciences at the Hutch, combined with a career-long involvement in the field of cell cycle and cancer biology to instill a fine-grained grasp of both the importance of a sound conceptual foundation and the disadvantages of a vision that’s too narrowly defined. Time spent in the Axel Lab during his student years at Columbia University overlapped with the discovery of gene transfer methods for mammalian cells, and helped lay the groundwork for an involvement with the Fred Hutchinson Cancer Research Center that now spans more than three decades. Jim Roberts’s career trajectory aligns precisely with the pioneering breakthroughs in the field of biotechnology. Harding University, BA, Political Science Harding University, BS, Public Administration With over 15 years of legal and commercial experience at these market-leading, innovative firms, he is well positioned to develop creative, win-win deal structures with other organizations. As senior attorney at the law firm Cooley LLC, his practice focused on equity financing and M&A transactions, and negotiating complex biotech licensing and collaboration deals. Prior to co-founding Lumen, Brian oversaw complex negotiations with various major biopharma companies and managed IP strategy for Adaptive Biotechnologies, where he was Senior Vice President and General Counsel. This is essential to an enterprise like Lumen, which is rethinking drug development from the ground up to emphasize speed, efficiency and ease of delivery, and whose approach is so innovative that traditional ways of thinking about IP and regulatory pathways oftentimes do not apply. Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |